An irradiated autologous tumor cell–based vaccine plus GM-CSF-producing and CD40L-expressing bystander cell line was tested among 24 refractory advanced NSCLC patients in a phase II trial assessing no tumor response [94]. The gene discussed is CSF2; the disease is neoplasm.